DILI, 25 june 2021(TATOLI)-Ministry of Health (MH) and World Health Organization (WHO) had declared that COVID-19 vaccination remains one of our most important measures.
Prevalence in response to current success of COVID-19, available risk of a person being infected, becoming seriously ill, being hospitalized or dying from COVID-19.
As new information and evidence becomes available, we are also evaluating, to continue our efforts and responses.
The continued safety and security of our community are our priority in every aspect of our efforts.
There are EIGHT COVID-19 vaccines, which received an emergency use license from WHO(EUL).
There are stringent safeguards to help ensure the safety of all vaccines
COVID-19.
Before receiving validation from WHO and National Regulatory Agencies,COVID-19 vaccines must undergo rigorous testing in clinical trials to prove that they meet internationally agreed benchmarks for safety and efficiency.
Almost 200,000 doses of COVID-19 vaccine have been administered in Timor-Leste and we do not have so far no reported cases of serious side effects. This is an amazing feat for a country that depends mainly on the AZ vaccine and is further proof of its safety vaccine in our population.
Regarding the safety of vaccines used in Timor-Leste, WHO and MH in Timor-Leste would like to reiterate a few points:
• The updated WHO interim recommendation issued on 21 April 2021 states
categorically that Oxford AstraZeneca) vaccine applicable by different pre-developed manufacturers for emergency use temp by clinical data essential for regulatory assessment. Consequences, these vaccines are safe and effective consideration for general use.
• As a recommendation from CSOs, they advocate continuing to administer the AZ vaccine for ages over 18 years.
• In the revised Australian recommendations, the AZ vaccine will continue to be administered to people over 60 years of age.
• In Australia, those under 60 years old, who took the first dose of AZ before June recommendations, are still receiving an AZ vaccine as the second dose (from
according to the recommendations of Australian regulators).
• Based on revised Australian recommendations, AstraZeneca vaccine can still
be used in adults under the age of 60, in situations where vaccine alternatives are not available.
After considering the current status of Covid-19 disease transmission and analysis, other countries also include age restrictions in place limiting the use of AZ vaccine as younger age groups. For example, there is no realm united, the age limit is 40 years.
• In countries with high transmission of the COVID-19 virus, such as Timor-Leste, benefits of vaccination (preventing people from contracting the COVID-19 cemetery of the disease, hospitalization and death) far outweigh the rare risk of contracting the syndrome
Thrombotic Thrombocytopenic (TTS) and hospitals for TTS deaths and deaths.
Australia’s decision does not change East Timor’s vaccination approach, given current community broadcasts and possible introduction of COVID-19 variants.
All individual operating systems those vaccinated in East Timor are at risk of contracting illness, hospitalization and death of COVID-19, an important referral that serious side effects after immunization with the vaccine AstraZeneca remains very rare.
Until now, there were no confirmed serious adverse events after immunization, including TTS, despite nearly 200,000 doses of AZ vaccine having been administered. This is a phenomenal feat not only in terms of our community joining to protect, but also from the tireless efforts of our vaccination teams to ensure that vaccines are being delivered to communities of all care in an appropriate way happily.
In addition, Timorese doctors are well trained and have the resources available treaties enforce if such rare incidents occur.
After extensive consultation with experts inside and outside WHO, they concluded satisfactorily that the benefits of the AZ vaccine far outweigh the risk.
Consequently, we confidently defend the continuation of COVID-19 vaccination using the Vaccine AZ.
Journalist: Camilio de Sousa
Editor: Rafy Belo
